February 4, 2016 News by Patricia Silva, PhD RRMS Drug Works by Shifting Anti-Inflammatory Immune Profile, Study Shows Researchers have found that changes in the compositionĀ of immune molecules ā specifically, a shift to more anti-inflammatory cytokines and regulatory T-cells (Tregs) ā likely account for the efficiencyĀ of alemtuzumab (Lemtrada) as a treatment for relapsing-remitting multiple sclerosis (RRMS). The study, titledĀ “Alemtuzumab long-term immunologic effect: Treg suppressor function…
December 3, 2015 by BioNews Staff Coral Gables, FL MS Exchange Event This Saturday To Explore Relapsing MS Management An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease.Ā The Coral Gables MS Exchange eventĀ will be held from 10:30 a.m. to 2:15 p.m. on…
November 10, 2015 News by Charles Moore Free MS Exchange Interactive Events Coming to San Antonio and Coral Gables (Miami) Two upcoming, free events for members of the multiple sclerosis community are to be held during the next few weeks at Coral Gables, Florida, and San Antonio, Texas, respectively. Sponsored by the pharmaceutical firm Genzyme, these interactive events will provide opportunities for peopleĀ with MS and members of the MS community…
October 12, 2015 News by Patricia Silva, PhD Update on Alemtuzumab (Genzyme’s Lemtrada) Clinical Trial Data Presented at ECTRIMS 2015 Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā held in Barcelona, Spain, October 7 to 10, 2015. On Friday, October 9, three parallel sessions entitled āFree Communicationsā took place. In the first session, several topics related to multiple…
October 9, 2015 News by Patricia Silva, PhD Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015 Genzyme, aĀ SanofiĀ company, recently announced novel positive 5-year experimental dataĀ from the extension study of LemtradaĀ®Ā (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS). The findings were presented today, October 9, at the 31stĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. LemtradaĀ®Ā (alemtuzumab), developedĀ by Genzyme, is…
June 23, 2015 News by Patricia Silva, PhD Canadian Drug Expert Committee Recommends MS Therapy LEMTRADA For Public Coverage The Canadian Drug Expert Committee (CDEC) recently recommended thatĀ LEMTRADAĀ (alemtuzumab) beĀ included in provincial and other public drug plansĀ for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS). The recommendation was madeĀ through Canada’sĀ Common Drug Review (CDR) and announced in a press releaseĀ by the company that…
May 14, 2015 News by admin PA Hospital Begins Offering LEMTRADA as Treatment for Relapsing Multiple Sclerosis The Allegheny General Hospital in Pennsylvania is now offering a new treatment option for people with relapsing remitting multiple sclerosisĀ (RRMS) — the most common form of multiple sclerosis.Ā Ā The treatment may help people with RRMS who have not responded to other medications. MS is an autoimmune disorder in which the…
May 1, 2015 News by admin Genzyme’s LEMTRADA Maintain’s Effectiveness in Reducing Brain Atrophy According to Recent Study Results GenzymeĀ presentedĀ new magnetic resonance imaging (MRI) data from the LemtradaĀ® (alemtuzumab) clinical development programĀ onĀ April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous…
November 17, 2014 News by Charles Moore Genzyme’s Lemtrada Approved by the FDA Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…
November 5, 2014 News by Patricia Silva, PhD Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient Sanofi subsidiary and rare disease treatment specialistĀ GenzymeĀ has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug forĀ relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…
October 2, 2014 News by Charles Moore QuĆ©bec Government Covers Lemtrada Second-line Treatment For Relapsing-remitting Multiple Sclerosis Genzyme, a Sanofi company, has announced that the Canadian province of QuĆ©bec’s Institut national d’excellence en santĆ© et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “MĆ©dicament d’exception” as a second-line treatment for…
September 9, 2014 News by Patricia Silva, PhD Genzyme’s Aubagio, Lemtrada MS Therapies To Showcase at Conference During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.
July 16, 2014 News by Patricia Silva, PhD Lemtrada For RRMS Still Under Review in the U.S., Now Approved in Scotland The Scottish Medicines Consortium (SMC) Ā announced the approval of the drug Lemtrada, produced byĀ Genzyme, for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) and active disease defined by clinical or imaging features, within the national health system (NHS) in Scotland. Lemtrada…
July 1, 2014 News by Patricia Silva, PhD MS Genzyme Drug Lemtrada Approved in Argentina, Still Under Review in US Lemtrada, a drug produced by GenzymeĀ for the treatment of adult patients suffering from relapsing remitting multiple sclerosis (RRMS) with active disease, was approved by Argentinaās National Administration of Drugs, Food and Medical Technology (ANMAT). “We are pleased by the continued global support for Lemtrada,” said Genzyme…
June 2, 2014 News by Charles Moore Genzyme Resubmits Multiple Sclerosis Drug Lemtrada For FDA sBLA Approval Review Cambridge, Mass. Based Genzyme, a Sanofi subsidiary, announced May 30 that the U.S. Food and Drug Administration (FDA) has accepted for review the companyās resubmission of its supplemental Biologics License Application (sBLA) seeking approval of its proprietary drug Lemtrada (alemtuzumab) for treatment of relapsing forms of multiple sclerosis (MS).